Archive for July 2021

There aren’t many of us back in the office thus far. When the rest of you arrive, it might get hairy. Read More

The nonprofit college for students seeking technical and trade careers has appointed Aisha Francis, Ph.D., to serve as the college’s president. Francis most recently served as BFIT’s CEO, a newly created role that she took on in August 2020 to help the college navigate remote and hybrid learning during the Covid-19 pandemic. Read More

Albireo Pharma, a rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for a drug for a pediatric liver disease called progressive familial intrahepatic cholestasis (PFIC). Read More

The governor testified virtually on Beacon Hill about his $2.9 billion plan for the state’s American Rescue Plan Act funding, the first in a series of legislative hearings about the best uses of the state’s funding windfall. Read More

The three museums, still closed because of the pandemic, say they’ll reopen in September after a roughly 18-month closure. Read More

A National Labor Relations Board judge has found the country’s largest cannabis company to have violated federal law, saying it discouraged unionization activities at its Hanover medical marijuana dispensary. Read More

These companies are not all household names, but each of their CEOs earned at least $100 million in total compensation in 2020. Here’s how. Read More

The news of the fundraise comes as another local venture firm announced the closing of its latest fund: Pillar VC, an early-stage venture firm launched in May 2016 and based in downtown Boston, said on Tuesday it closed a total of $192 million of capital for Pillar III and Pillar Select, the firm’s latest venture…

The brainchild of two Harvard classmates began as a mission to develop a way for surgeons to be able to deploy surgical guidance and robotics at the point of patient care. Read More

Biotech startup Cellarity has a new chief financial officer whose former job it was to analyze and occasionally criticize biotech companies and their funding models. Read More